Emily N. Arner

Emily N. Arner

Auto-generated profile, based on publicly available information

Emily N. Arner

Department of Medicine, Vanderbilt University Medical Center, Nashville, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JBJackie E. Bader
Jackie E. Bader
MWMelissa M. Wolf
Melissa M. Wolf
GLGian Luca Lupica-Tondo
Gian Luca Lupica-Tondo
MMMatthew Z. Madden
Matthew Z. Madden
BRBradley I. Reinfeld
Bradley I. Reinfeld
JRJeffrey C. Rathmell
Jeffrey C. Rathmell

13 January 2023 in Science Immunology
Verified
Journal Article
Closed access
KVKelsey Voss
Kelsey Voss
ASAllison E. Sewell
Allison E. Sewell
EKEvan S. Krystofiak
Evan S. Krystofiak
KGKatherine Gibson-Corley
Katherine Gibson-Corley
AYArissa C. Young
Arissa C. Young
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
T cells in systemic lupus erythematosus (SLE) exhibit multiple metabolic abnormalities. Excess iron can impair mitochondria and may contribute to SLE. To gain insights into this potential role of iron in SLE, we performed a CRISPR screen of iron handling genes on T cells. Transferrin receptor (CD71) was identified as differentially critical for T H 1 and inhibitory for induced regulatory T cells (iT regs ). Activated T cells induced CD71 and iron uptake, which was exaggerated in SLE-prone T cells. Cell surface CD71 was enhanced in SLE-prone T cells by increased endosomal recycling. Blocking CD71 reduced intracellular iron and mTORC1 signaling, which inhibited T H 1 and T H 17 cells yet enhanced iT regs . In vivo treatment reduced kidney pathology and increased CD4 T cell production of IL-10 in SLE-prone mice. Disease severity correlated with CD71 expression on T H 17 cells from patients with SLE, and blocking CD71 in vitro enhanced IL-10 secretion. T cell iron uptake via CD71 thus contributes to T cell dysfunction and can be targeted to limit SLE-associated pathology.

11 June 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
BKBlaise Russel Kimmel
Blaise Russel Kimmel
KAKaran Arora
Karan Arora
NCNeil C. Chada
Neil C. Chada
VBVijaya Bharti
Vijaya Bharti
AKAlexander J. Kwiatkowski
Alexander J. Kwiatkowski
JWJohn T. Wilson
John T. Wilson
The enhancement of antitumour immunity via agonists of the stimulator of interferon genes (STING) pathway is limited by pharmacological barriers. Here we show that the covalent conjugation of a STING agonist to anti-albumin nanobodies via site-selective bioconjugation chemistries prolongs the circulation of the agonist in the blood and increases its accumulation in tumour tissue, stimulating innate immune programmes that increased the infiltration of activated natural killer cells and T cells, which potently inhibited the growth of mouse tumours. The technology is modular, as demonstrated by the recombinant integration of a second nanobody domain targeting programmed death-ligand 1 (PD-L1), which further increased the accumulation of the agonist in tumours while blocking immunosuppressive PD-1/PD-L1 interactions. The bivalent nanobody–STING agonist conjugate stimulated robust antigen-specific T-cell responses and long-lasting immunological memory and conferred enhanced therapeutic efficacy. It was also effective as a neoadjuvant treatment to adoptive T-cell therapy. As a modular approach, hitchhiking STING agonists on serum albumin may serve as a broadly applicable strategy for augmenting the potency of systemically administered cancer immunotherapies.

20 September 2024 in Science Immunology
Verified
Journal Article
Closed access
DHDarren R. Heintzman
Darren R. Heintzman
RSRachael C. Sinard
Rachael C. Sinard
EFEmilie L. Fisher
Emilie L. Fisher
XYXiang Ye
Xiang Ye
APAndrew R. Patterson
Andrew R. Patterson
JRJeffrey C. Rathmell
Jeffrey C. Rathmell
Heat is a cardinal feature of inflammation, yet its impacts on immune cells remain uncertain. We show that moderate-grade fever temperatures (39°C) increased murine CD4 T cell metabolism, proliferation, and inflammatory effector activity while decreasing regulatory T cell suppressive capacity. However, heat-exposed T helper 1 (T H 1) cells selectively developed mitochondrial stress and DNA damage that activated Trp53 and stimulator of interferon genes pathways. Although many T H 1 cells subjected to such temperatures died, surviving T H 1 cells exhibited increased mitochondrial mass and enhanced activity. Electron transport chain complex 1 (ETC1) was rapidly impaired under fever-range temperatures, a phenomenon that was specifically detrimental to T H 1 cells. T H 1 cells with elevated DNA damage and ETC1 signatures were also detected in human chronic inflammation. Thus, fever-relevant temperatures disrupt ETC1 to selectively drive apoptosis or adaptation of T H 1 cells to maintain genomic integrity and enhance effector functions.

1 October 2018 in Molecular Metabolism
Verified
Journal Article
Open access
VCVictoria H. Cruz
Victoria H. Cruz
EAEmily N. Arner
Emily N. Arner
KWKatherine W. Wynne
Katherine W. Wynne
PSPhilipp E. Scherer
Philipp E. Scherer
Rolf BrekkenRolf Brekken
Rolf Brekken
TANK Binding Kinase 1 (TBK1) has been implicated in the regulation of metabolism through studies with the drug amlexanox, an inhibitor of the IκB kinase (IKK)-related kinases. Amlexanox induced weight loss, reduced fatty liver and insulin resistance in high fat diet (HFD) fed mice and has now progressed into clinical testing for the treatment and prevention of obesity and type 2 diabetes. However, since amlexanox is a dual IKKε/TBK1 inhibitor, the specific metabolic contribution of TBK1 is not clear. To distinguish metabolic functions unique to TBK1, we examined the metabolic profile of global Tbk1 mutant mice challenged with an obesogenic diet and investigated potential mechanisms for the improved metabolic phenotype. We report that systemic loss of TBK1 kinase function has an overall protective effect on metabolic readouts in mice on an obesogenic diet, which is mediated by loss of an inhibitory interaction between TBK1 and the insulin receptor.

2 May 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
VCVictoria H. Cruz
Victoria H. Cruz
EAEmily N. Arner
Emily N. Arner
WDWenting Du
Wenting Du
ABAlberto E. Bremauntz
Alberto E. Bremauntz
Rolf BrekkenRolf Brekken
Rolf Brekken
Pancreatic ductal adenocarcinoma (PDA) is characterized by an activating mutation in KRAS . Direct inhibition of KRAS through pharmacological means remains a challenge; however, targeting key KRAS effectors has therapeutic potential. We investigated the contribution of TANK-binding kinase 1 (TBK1), a critical downstream effector of mutant active KRAS, to PDA progression. We report that TBK1 supports the growth and metastasis of KRAS-mutant PDA by driving an epithelial plasticity program in tumor cells that enhances invasive and metastatic capacity. Further, we identify that the receptor tyrosine kinase Axl induces TBK1 activity in a Ras-RalB–dependent manner. These findings demonstrate that TBK1 is central to an Axl-driven epithelial-mesenchymal transition in KRAS-mutant PDA and suggest that interruption of the Axl/TBK1 signaling cascade above or below KRAS has potential therapeutic efficacy in this recalcitrant disease.